tiprankstipranks
Trending News
More News >

PharmaDrug’s Cepharanthine Shows Potential Against Monkeypox

Story Highlights
PharmaDrug’s Cepharanthine Shows Potential Against Monkeypox

Pharmadrug (TSE:PHRX) has released an update.

Confident Investing Starts Here:

PharmaDrug’s subsidiary Sairiyo Therapeutics has reported that cepharanthine, a component of their PD-001 drug, shows promise in binding to key proteins of the monkeypox virus, which could aid in the development of new treatments. The company is cautiously optimistic about PD-001’s potential as a multi-indication antiviral and is proceeding to Phase 1 clinical trials for its application in medical countermeasures and cancer, without claiming current efficacy in treating monkeypox.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App